AB Science SA · EURONEXT:AB
AB Science SA — Investor Presentation (February 2023)
28 slides from AB Science SA's investor presentation, February 2023
Slide 1: Corporate Presentation
Corporate Presentation February 2023
Slide 2: Disclaimer
Disclaimer This presentation, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such presentation in certain jurisdiction may constitute a breach of applicable
Slide 3: Overview
Overview Management Team Stock Information ALAIN MOUSSY OLIVIER HERMINE, Co-founder and CEO Listed on Euronext Compartment B MD, PhD Co-founder and ISIN : FR0010557264 Former strategic consultant at Booz, Allen Chairman of Scientific Committee & Hamilton and former Head of Corporate Tickers :
Slide 4: Pipeline
Pipeline AB Science has a diversified and late-stage portfolio with masitinib being a platform Therapeutic Confirmatory Conditional Compound Class Indication Preclinical Phase 1 Phase 2 Phase 2B/3 area Phase 3 Approval Under review in Amyotrophic Lateral Sclerosis* On-going confimatory study Canada
Slide 5: Masitinib blockbuster potential in unmet medical needs
Masitinib Masitinib has a blockbuster potential in unmet medical needs, both in large and orphan diseases Estimated Annual Therapeutic Annual Treatment Nber of patients area Indications Available treatments List Price (in USD) (USA and EU) Alzheimer’s disease 5 000 000 Aduhelm (in early AD) 28,200 (
Slide 6: Masitinib core development is in Central Nervous System
Masitinib Masitinib core development is in Central Nervous System Rationale Indications Large phases 2B/3 Phase 2B/3 Ongoing confirmatory completed Publication phases 3 • 394 patients enrolled. • Mora 2020 (main study) • Actively Recruiting (USA & EU) Modulation Amyotrophic • Primary endpoint met •
Slide 7: Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis Phase 2B/3 demonstrated with masitinib 4.5 mg/kg/day a significant delay of disease progression over a 48- week period in the primary analysis population and significant OS benefit in subgroup of patients with moderate ALS Normal Progressors (Primary Endpoint) : 27% slo
Slide 8: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Benefit on functional score (ALSFRS-R) was supported by improvement in secondary endpoints in (time to disease progression or death (PFS), quality of life, and respiratory function) 25% delay in disease progression (PFS): +4 months 28% improvement in quality of life al)
Slide 9: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Results from phase 2B/3 and long-term survival were published in two peer-reviewed journals 9
Slide 10: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Confirmatory phase 3 study is authorized by FDA and key European countries and actively enrolling patients Primary endpoint 150+15 Masitinib 6.0mg/kg/day Change in the ALSFRS-R Randomizatioion + Riluzole Last patient Last score at week 48 visit week 48 Extension Scree
Slide 11: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis There is a need for combination of treatments in ALS due to the multifactorial nature of the disease and Masitinib is the only drug with confirmatory trial having the same duration at week 48 as the first pivotal study Status Drug Mechanism of action Development plan Fi
Slide 12: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Masitinib has two pending regulatory decisions in ALS for conditional approval in Europe and Canada • Notice of Compliance with conditions (NOC/c) filing accepted in April 2022 • Notice of Deficiency (NOD) issued in December 2022 • AB Science intends to respond to defic
Slide 13: Multiple sclerosis
Multiple sclerosis Phase 2B/3 demonstrated a significant benefit on disability progression with masitinib 4.5 mg/kg/day in patients with advanced stage of the disease Significant reduction in progression on EDSS (Primary Endpoint*) Patients were enrolled at advanced disease stage Median age (years
Slide 14: Multiple sclerosis
Multiple sclerosis Phase 2B/3 demonstrated a significant reduction of risk of first disability progression by 42% and a reduction of risk of confirmed (12-week) disability progression by 37% 42% risk reduction of time to disability progression 37% risk reduction of time to confirmed disability progr
Slide 15: Multiple sclerosis
Multiple sclerosis Masitinib has the potential to become a best-in-class drug for PPMS and nSPMS Time to confirmed disability progression Reduction in confirmed Study Size Drug Type of Progressive MS Hazard Ratio (3 months) disability (patients) progression Masitinib 4.5 mg/kg/day 300 PPMS and nSPMS
Slide 16: Multiple sclerosis
Multiple sclerosis Results from phase 2B/3 were published in peer-reviewed journal 16
Slide 17: Multiple sclerosis
Multiple sclerosis Confirmatory phase 3 study is authorized by FDA and key European countries and actively enrolling patients Primary endpoint Time to confirmed (12-week CDP) EDSS progression 400 Randomizatioion Masitinib 4.5mg/kg/day Main secondary endpoints End of Study 24-weeks CDP Screening
Slide 18: Multiple Sclerosis
Multiple Sclerosis There is no approved drugs for non-active SPMS and only one for PPMS, and very few drugs into phase 3 Indications Distribution of patients Approved Drugs in phases 3 Differentiating factors (Nbr EU + USA) treatments • Masitinib Masitinib Positioning Primary 15% Ocrevus (Roche) • T
Slide 19: Alzheimer's disease
Alz heimer’s disease Phase 2B/3 study demonstrated a significant reduction in cognitive impairment based on ADAS-COG (p=0.0003) and improvement on daily activity based on ADCS-ADL (p=0.0381) with masitinib 4.5 mg/kg/day Significant effect on cognitive function after 24 weeks of treatment Change in A
Slide 20: Alzheimer's disease
Alz heimer’s disease Results from phase 2B/3 were presented at the 2021 Alzheimer’s Association International Conference (AAIC) 20
Slide 21: Alzheimer's disease
Alz heimer’s disease Confirmatory phase 3 study is authorized by FDA and key European countries and initiating patients enrolment Primary endpoint Change from baseline in ADCS-ADL score at week 24, and 300 Change from baseline in ADAS-Cog 11 score Randomizatioion Extension period Masitinib 4.5mg
Slide 22: Alzheimer's disease
Alz heimer’s disease Alzheimer’s treatments are predominantly antibodies targeting amyloid plaques for the treatment of early Alzheimer’s disease Indications Drug MMSE Reduction in clinical decline Differentiating factors (Severity) + - ADAS-Cog* ADCS-ADL** CDR-SB Masitinib Mild Moderate Oral trea
Slide 23: Masitinib clinical program outside of neurology
Masitinib clinical program outside of neurology Advanced pipeline in oncology and inflammatory diseases can add value to the neurology plateform Therapeutic area Indication Results Development Status First phase 3 completed (135 patients) Confirmatory phase 3 ongoing Indolent systemic mastocytos
Slide 24: Mastocytosis
Mastocytosis Phase 3 demonstrated a significant reduction in symptoms with masitinib at 6.0 mg/kg/day 3.6 fold improvement in most prevalent symptoms Improvement in objective markers of the disease Masitinib Placebo p-value Odds ratio Masitinib Placebo p-value 4H75% Primary pruritus, flushes, depres
Slide 25: Mastocytosis
Mastocytosis Results from phase 3 were published in The Lancet 25
Slide 26: AB8939
AB8939 AB8939 is a novel Microtubule-destabilizing drug able to cure mice with patient derived xenograft of Acute megakaryoblastic leukemia Detection of AMKL26 PDX blasts in mice Activity of AB8939 in Ara-C Key Differentiating factors following single agent AB8939 treatment resistant/refractory AML
Slide 27: AB8939 Phase 1/2 in refractory AML
AB8939 Phase 1/2 in refractory Acute Myeloid Leukemia is authorized by FDA and key European countries and actively enrolling patients Phase 1/2 design Phase 1/2 Objectives Design: Open-label, Uncontrolled, Multiple Doses, phase 1 study Main inclusion criteria: Patients with documented diagnosis of
Slide 28: Licensing
Licensing An investment bank has been mandated to seek potential licensing options for masitinib Clinical development and/or commercialization of masitinib Scope In one indication, or neurology, or all indications In one key country, or one region, or all countries Advanced program in neurol